Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Paola Guglielmelli, Chiara Maccari, Manjola Balliu, Giuseppe Gaetano Loscocco, Naseema Gangat, Alessandro Atanasio, Paolo Cicogna, Leonardo Signori, Giada Rotunno, Niccolò Bartalucci, Gloria Nanni, Anna Catelani, Rossella Manfredini, Chiara Paoli, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 144 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2024-198891

Published: 2024

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 237.

https://doi.org/10.1182/blood-2021-147869

Published: 2021

Journal Articles

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Blood (2021) 138 (Supplement 1): 236.

https://doi.org/10.1182/blood-2021-145116

Published: 2021

Journal Articles

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Blood (2020) 136 (2): 171–182.

https://doi.org/10.1182/blood.2019004596

Published: 2020

Includes: Supplemental data

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro M. Vannucchi, Paola Guglielmelli

Blood (2019) 133 (26): 2802–2808.

https://doi.org/10.1182/blood.2018879536

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Paola Guglielmelli, MD PhD, Giacomo Coltro, MD, Giuseppe Gaetano Loscocco, MD, Benedetta Sordi, MD, Francesco Mannelli, MD, Chiara Paoli, PhD, Ilaria Marone, PhD, Alessandro Pancrazzi, PhD, Francesca Gesullo, BSci, Carmela Mannarelli, PhD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2018-99-112287

Published: 2018

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Blood (2017) 129 (24): 3227–3236.

https://doi.org/10.1182/blood-2017-01-761999

Published: 2017

Includes: Supplemental data

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Elisa Rumi, MD, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Mario Cazzola, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1615.

https://doi.org/10.1182/blood.V126.23.1615.1615

Published: 2015

Journal Articles

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Blood (2015) 126 (23): 1602.

https://doi.org/10.1182/blood.V126.23.1602.1602

Published: 2015

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2015) 125 (21): 3352–3353.

https://doi.org/10.1182/blood-2015-01-624536

Published: 2015

Journal Articles

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Lisa Pieri, MDPhD, Alessandro Pancrazzi, MSc, Annalisa Pacilli, PhD, Claudia Rabuzzi, BSci, Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, MSc, Tiziana Fanelli, MSc, Alberto Bosi, MD, Srdan Verstovsek, MD PhD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 3185.

https://doi.org/10.1182/blood.V124.21.3185.3185

Published: 2014

Journal Articles

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Blood (2014) 124 (21): 3192.

https://doi.org/10.1182/blood.V124.21.3192.3192

Published: 2014

NARROW

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only